Highlights from ATTD 2022 - Diatribe
May 6, 2022 7:39:09 GMT -5
oldfishtowner, dh4mizzou, and 3 more like this
Post by sayhey24 on May 6, 2022 7:39:09 GMT -5
From Diatribe - diatribe.org/biggest-news-diabetes-technology-highlights-attd-2022
Where do you start to dissect this - maybe we start with our old friend Edelman who is now getting into the T2 space big time. They are just now starting to realize CGM use in the T2 space would be a really good thing. Steve gave a debrief on the MOBILE clinical study. This was about T2's on basal using a CGM.
Steve's take away was "there was large variability within the group using CGM, leaving questions about why people with type 2 diabetes responded to CGMs inconsistently"
Is that surprising? First, the first thing these people lose is post prandial glucose control - aka first phase insulin release. Basal insulin is going to do nothing to help with the post meal spike. These PWDs needed to treat the post meal spike with food and exercise. I have to believe this is a huge variable with a group which started with an A1c at 9+.
How about we redo the Mobile clinical study with an afrezza arm? At this point all we need to do is add an arm adding afrezza for prandial control. We don't need to redo the basal CGM and BGM arms. I bet Edelman could knock the ball out of the park with afrezza and significantly reduce the inconsistency.
Where do you start to dissect this - maybe we start with our old friend Edelman who is now getting into the T2 space big time. They are just now starting to realize CGM use in the T2 space would be a really good thing. Steve gave a debrief on the MOBILE clinical study. This was about T2's on basal using a CGM.
Steve's take away was "there was large variability within the group using CGM, leaving questions about why people with type 2 diabetes responded to CGMs inconsistently"
Is that surprising? First, the first thing these people lose is post prandial glucose control - aka first phase insulin release. Basal insulin is going to do nothing to help with the post meal spike. These PWDs needed to treat the post meal spike with food and exercise. I have to believe this is a huge variable with a group which started with an A1c at 9+.
How about we redo the Mobile clinical study with an afrezza arm? At this point all we need to do is add an arm adding afrezza for prandial control. We don't need to redo the basal CGM and BGM arms. I bet Edelman could knock the ball out of the park with afrezza and significantly reduce the inconsistency.
